Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
HA-100
Cat. No.:
0225LY-1084
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
HA-100 is categorized as an inhibitor of protein kinases.
Synonym:
84468-24-6; ha-100; 1-(5-Isoquinolinesulfonyl)piperazine; 5-(piperazin-1-ylsulfonyl)isoquinoline; Isoquinoline,5-(1-piperazinylsulfonyl)-; C-1; 5-(piperazine-1-sulfonyl)isoquinoline; 5-piperazin-1-ylsulfonylisoquinoline; HA 100 (pharmaceutical); Tocris-0543; 1-(5-Isoquinolinylsulfonyl)piperazine; C-I-QP; 1-(5-Isoquinolinesulfonyl)piperazine, dihydrochloride; 5-(1-Piperazinylsulfonyl)isoquinoline; Piperazine, 1-(5-isoquinolinylsulfonyl)-
CAS No.:
84468-24-6
Compound CID:
3545
Formula:
C13H15N3O2S
Formula Weight:
277.34
Specification
Targets&IC50:
PKG: 4 μM ; PKC: 12 μM; PKC: 6.5 μM (Ki); PKA: 8 μM ; MLCK: 240 μM ; MLCK: 61 μM (Ki)
Relative Density:
1.332 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
HA-100 can be used in cardiovascular studies to investigate the relaxation of smooth muscles through the inhibition of Rho-kinase and PKA.
Library Information
Target:
Myosin; PKA; PKC
Receptor:
Myosin; PKA; PKC
Pathways:
Tyrosine kinase/adaptors; Cytoskeletal signaling; Chromatin/Epigenetic
Plate Number:
AOCL-14
Plate Location:
h10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
150 mg/mL; 540.85 mM





